Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Hemab Therapeutics Holdings, Inc. Common Stock
Market Cap
$1.34B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
EBITDA Margin
-10195.54%
TTM Avg
-87388.52%
3Y Avg
-48181.08%
5Y Avg
-32386.50%
Market Cap
$1.43B
EBITDA Margin
21.45%
TTM Avg
-50.92%
3Y Avg
-538.26%
5Y Avg
-378.46%
Market Cap
$1.46B
EBITDA Margin
36.35%
TTM Avg
36.35%
3Y Avg
36.35%
5Y Avg
36.35%
Market Cap
$1.47B
EBITDA Margin
3.56%
TTM Avg
3.76%
3Y Avg
3.79%
5Y Avg
3.46%
Market Cap
$1.22B
EBITDA Margin
8.83%
TTM Avg
3.81%
3Y Avg
0.53%
5Y Avg
2.86%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG) | $1.34B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.37B | N/A | N/A | N/A | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.32B | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | -10195.54% | -87388.52% | -48181.08% | -32386.50% |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 21.45% | -50.92% | -538.26% | -378.46% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | 36.35% | 36.35% | 36.35% | 36.35% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.47B | 3.56% | 3.76% | 3.79% | 3.46% |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 8.83% | 3.81% | 0.53% | 2.86% |
| Kardigan, Inc. (KARD)vs › | $1.23B | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
